Bank of America Corp DE trimmed its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ: IMCR)

Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-

JP Morgan analyst Jessica Fye reinstates Immunocore Holdings (NASDAQ:IMCR) with a Overweight and

Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed si

Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation a

Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocki

IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.

The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Im

Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript

Immunocore NASDAQ: IMCR reported continued growth for KIMMTRAK in the second quarter and first half

Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.02) per share which missed the analy

Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (teben

Mizuho analyst Graig Suvannavejh maintains Immunocore Holdings (NASDAQ:IMCR) with a Neutral and r

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSH

IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to

Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep invest

Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, in

Immunocore has transitioned from a rare-disease oncology company to a self-funded platform company w

IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced

The average of price targets set by Wall Street analysts indicates a potential upside of 111.5% in I

Immunocore Hldgs (NASDAQ:IMCR) reported quarterly earnings of $0.25 per share which beat the analyst

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR)

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients wi

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR)

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the

Jefferies analyst Clara Dong downgrades Immunocore Holdings (NASDAQ:IMCR) from Buy to Hold and lo

Needham analyst Gil Blum maintains Immunocore Holdings (NASDAQ:IMCR) with a Buy and raises the pr

Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.60) per share which missed the analy

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR)

Morgan Stanley analyst Andrew Galler maintains Immunocore Holdings (NASDAQ:IMCR) with a Equal-Wei

Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activityIMC-I1

Immunocore Hldgs (NASDAQ:IMCR) reported quarterly sales of $103.693 million which beat the analyst c

Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Immunocore Holdings (NASDAQ:IMCR) wi

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR)

Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.20) per share which beat the analyst

https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-r

HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) wit

Oppenheimer analyst Jeff Jones maintains Immunocore Holdings (NASDAQ:IMCR) with a Outperform and

Immunocore Hldgs (NASDAQ:IMCR) reported quarterly earnings of $0.10 per share which beat the analyst

JP Morgan analyst Jessica Fye maintains Immunocore Holdings (NASDAQ:IMCR) with a Overweight and l

Needham analyst Gil Blum reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $7